RNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. While the near-term technical setup is constructive, upside looks capped near resistance and multiple fundamentals/sentiment factors (heavy insider selling, softening P&C pricing-cycle commentary, and weak YoY quarterly trends) make the risk/reward unattractive for an impatient buyer at ~$280 ahead of earnings (2026-02-03).
Trend/structure is bullish but close to resistance: SMA_5 > SMA_20 > SMA_200 confirms an uptrend and MACD histogram (+0.52) is positive and expanding (momentum improving). RSI_6 at ~63 is neutral-to-slightly-warm, not yet overbought. Key levels: Pivot 275.47 is the near-term line in the sand; first resistance R1 281.00 is immediately overhead (price ~280.06), then R2 284.42. Support sits at 269.94 then 266.52. Given price is pressing R1, the current entry is less attractive unless it cleanly breaks and holds above ~281–284. Also note the pattern-based projection indicates elevated 1-month downside bias (-8.56%), which argues against chasing strength right here.
Intellectia Proprietary Trading Signals
Near-term technical momentum is positive (bullish moving averages; MACD expanding). Multiple firms raised price targets recently (Barclays, TD Cowen, Evercore, JPMorgan, Keefe Bruyette, Morgan Stanley), implying Wall Street sees some upside from current levels. Potential event catalyst: QDEC 2025 earnings on 2026-02-03 (after hours) could reset expectations if results/forward commentary beat.
Pattern-based forecast suggests increased 1-month downside risk (-8.56%). No supportive news flow in the last week to counterbalance these risks. Earnings on 2026-02-03 adds near-term event risk for an impatient entry.
Latest reported quarter: 2025/Q3. Revenue fell to 3.112B (-7.35% YoY), net income fell to 892.6M (-22.77% YoY), and EPS fell to 19.4 (-14.24% YoY). The YoY trend is clearly negative across top-line and profitability, which aligns with the broader narrative that the cycle is getting more challenging.
Recent analyst activity shows a wave of price target increases in early Jan 2026, but ratings are mostly Neutral/Hold/Equal Weight/Market Perform (Barclays Equal Weight; TD Cowen Hold; Evercore In Line; JPMorgan Neutral; Keefe Bruyette Market Perform; Mizuho Neutral). Morgan Stanley remains Overweight, while Goldman stays Sell despite raising its target. Wall Street ‘pros’ case: targets moved up and valuation/sentiment may already reflect some headwinds; technicals are supportive. ‘Cons’ case: multiple firms explicitly cite softening pricing/competition and a tougher 2026 setup, with at least one bearish house (Goldman) warning Street estimates may be too optimistic.
